Zydus has announced biological therapy ZRC-3308, used to treat mild COVID-19. The pharmaceutical company now seeks DCGI (Drugs Controller General of India) nod to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection.
In a statement, Dr Sharvil Patel, Managing Director of Cadila Healthcare Limited, said they believe that ‘biological therapy’ ZRC-3308 – ‘a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs)’, has the potential to address concerns abut the progression of the disease.
In a press release, the pharmaceutical company said the ZRC-3308 is designed to have a “long half-life providing protection for a long period of time” and has “reduced immune-effector to minimize potential tissue-damaging side effects of virus neutralising monoclonal antibodies thereby providing a safer product.”
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…
Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…
Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…
In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…